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ABSTRACT
Objectives  To describe the efﬁ  cacy and safety through 
5 years of adalimumab treatment in patients with 
ankylosing spondylitis (AS), and to identify predictors of 
remission.
Methods  Patients with active AS were followed up to 
5 years during a 24-week randomised, controlled period, 
followed by an open-label extension. Disease activity and 
clinical improvement were evaluated by Assessment in 
Spondyloarthritis International Society (ASAS) responses, 
Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and Ankylosing Spondylitis Disease Activity 
Score (ASDAS). Kaplan–Meier was used to identify 
patients with sustained ASAS partial remission (PR) or 
ASDAS inactive disease (ID) for three or more consecutive 
visits spanning ≥6 months. Logistic regression was used 
to identify factors associated with remission. Explanatory 
variables included baseline demographic and disease 
characteristics and week 12 responses.
Results  Of the 311 patients who received at least one 
dose of adalimumab, 202 (65%) completed the 5-year 
study. Among 125 patients who received 5 years of 
adalimumab, 70%, 77%, 51% and 61% achieved ASAS40, 
BASDAI 50, ASAS PR and ASDAS ID, respectively. 
Of 311 adalimumab-treated patients, 45% and 55% 
achieved sustained ASAS PR and ASDAS ID at any time 
during study participation. The strongest predictor of 
remission at years 1 and 5 and of sustained remission 
was achieving remission at 12 weeks of treatment; 
baseline characteristics showed weaker associations. 
Adverse events were comparable with previous reports 
on adalimumab safety.
Conclusions  In patients with active AS, the efﬁ  cacy and 
safety of adalimumab were maintained through 5 years 
with about half of the patients experiencing sustained 
remission at any time during the study. Early achievement 
of remission was the best predictor of long-term and 
sustained remission.
INTRODUCTION
Ankylosing spondylitis (AS) is a spondyloarthritis 
that presents with predominantly axial manifes-
tations. Patients with AS may have inﬂ  ammation 
of the spine, sacroiliac joints, peripheral joints and 
entheses.
Randomised controlled trials have consistently 
demonstrated the efﬁ   cacy and safety of tumour 
necrosis factor (TNF) α inhibitors in reducing the 
signs and symptoms associated with AS.1–4 TNF 
inhibitors are the only class of drugs in addition to 
non-steroidal anti-inﬂ   ammatory drugs (NSAIDs) 
proved to be effective for the axial component of AS, 
as reﬂ  ected in the Assessment in Spondyloarthritis 
International Society (ASAS)/EULAR recommen-
dations for the management of AS.5 Open-label 
extension studies support a sustained treatment 
effect for TNF inhibitors,6–9 but longer-term data 
are limited by small sample populations.10 11 The 
need for chronic disease management makes long-
term data on effective treatments of clinical impor-
tance for both doctors and patients.
The ASAS consensus statement on the use of TNF 
inhibitors in axial spondyloarthritis recommends 
evaluating treatment response at least 12 weeks 
after initiation of TNF inhibitor treatment based on 
reductions in Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) scores and the doctor’s 
expert opinion to determine if TNF inhibitor use 
should continue.12 However, the implications of 
early treatment response on long-term disease 
control have not been fully explored. One report 
noted that a response at week 2 to inﬂ  iximab, but 
not baseline disease characteristics, was associated 
with subsequent short-term clinical response.13 
On the other hand, studies with inﬂ  iximab, etan-
ercept and/or adalimumab identiﬁ  ed age, disease 
duration and baseline disease characteristics (raised 
C-reactive protein (CRP), erythrocyte sedimenta-
tion rate, enthesitis, total back pain, BASDAI, Bath 
Ankylosing Spondylitis Functional Index (BASFI), 
human leucocyte antigen (HLA)-B27 positivity 
and lack of previous exposure to TNF inhibitors) 
as predictors of clinical response.14–20 These reports 
looked only at predictors of clinical response at 6 
months or earlier and largely focused on improve-
ment (ie, ASAS20, BASDAI 50).
The Adalimumab Trial evaluating Long-term efﬁ  -
cacy and safety in AS (ATLAS) trial was a global, mul-
ticentre study of adalimumab in patients with active 
AS.1 This report summarises the clinical efﬁ  cacy and 
safety of adalimumab through the end of the 5-year 
ATLAS trial and uses the efﬁ  cacy data to determine 
predictors of long-term remission at years 1 and 5 and 
of sustained remission with adalimumab treatment.
PATIENTS AND METHODS
Patients
Patients were ≥18 years of age, diagnosed with AS 
using the modiﬁ  ed New York criteria,21 and had 
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was assessed for continuous independent disease-state vari-
ables. Categorical independent variables included sex, presence 
of HLA-B27, abnormal baseline CRP (≥0.49 mg/dl), presence of 
baseline syndesmophytes and response after 12 weeks of adali-
mumab treatment as measured by the following outcome vari-
ables: ASAS20, ASAS40, ASAS PR, ASDAS ID, ASDAS MI and 
BASDAI 50.
Multivariate regression analysis of sustained remission
Kaplan–Meier survival curve analysis was used to determine 
the proportion of patients with sustained remission, deﬁ  ned as 
achieving ASAS PR or ASDAS ID on adalimumab treatment for 
at least three consecutive study visits spanning a period of at 
least 6 months at any point during the 5-year study. Patients 
were censored if they withdrew prematurely from the trial. All 
variables considered in the univariate analysis for long-term 
remission were included in multivariate regression for sustained 
remission; additionally, the original treatment assignment was 
added as an explanatory variable to determine if achieving sus-
tained remission differed based on initial randomisation. The 
analysis was performed for all patients with data available for 
all independent variables.
RESULTS
Patient disposition and characteristics
Data were collected from January 2004 through July 2009. Of 
the 315 patients enrolled, 208 patients were randomised to adal-
imumab and 107 to placebo. This analysis included 311 patients 
who received at least one dose of adalimumab during the dou-
ble-blind or open-label portions of the trial (‘any adalimumab 
exposure’ set). This population was representative of patients 
with established AS: primarily male, white, HLA-B27-positive 
and with long disease duration (table 1).
Through 5 years, 113/315 (36%) randomised patients dis-
continued the study, including 109/311 (35%) patients with at 
least one dose of adalimumab. Investigators may have identi-
ﬁ  ed more than one reason for discontinuation, which was most 
commonly listed as due to adverse events, in 38/311 (12%) 
patients and withdrawal of consent, in 37/311 (12%) patients. 
The median duration of exposure to adalimumab among the 
311 patients was 4.8 years (interquartile range 2.8–5.0 years).
active disease based on the presence of at least two of the fol-
lowing three criteria: BASDAI score ≥4, total back pain score 
≥40 mm (on a 0–100 mm visual analogue scale (VAS)) and/or 
morning stiffness ≥1 h. Patients must have had an inadequate 
response to, or intolerance of, NSAIDs. More detailed inclusion 
and exclusion criteria have been previously published.1
Study design
The ATLAS study was a phase 3, randomised, double-blind, 
placebo-controlled, multicentre trial conducted at 43 sites in the 
USA and Europe, designed to evaluate the safety and efﬁ  cacy 
of adalimumab in patients with active AS (NCT00085644).1 
Patients were randomised 2:1 to adalimumab (40 mg every 
other week) or placebo for 24 weeks of double-blind treatment, 
followed by the option to continue with open-label adalimumab 
in an extension period for up to a total of 5 years of study par-
ticipation. Patients who failed to achieve an ASAS20 response 
by week 12 were eligible for early escape treatment with open-
label adalimumab. The study was conducted with the approval 
of the appropriate institutional ethics review board and with 
voluntary written informed patient consent.
Clinical and safety measures
Baseline demographics and disease characteristics were sum-
marised at study entry. Efﬁ  cacy and safety outcomes after 24 
weeks and 2 years have been previously published.1 6 Efﬁ  cacy 
assessments deﬁ   ned baseline as the last observation before 
the ﬁ  rst adalimumab dose, either blinded or open-label. ASAS 
partial remission (ASAS PR) was deﬁ  ned as a value of ≤2 (on a 
0–10 scale) for all four domains: patient global assessment of 
disease activity, pain, function (BASFI) and inﬂ  ammation (mean 
of BASDAI questions 5 and 6).22 The Ankylosing Spondylitis 
Disease Activity Score (ASDAS) was calculated from patient 
global assessment of disease activity (VAS), total back pain 
(BASDAI question 2), peripheral pain/swelling (BASDAI ques-
tion 3), duration of morning stiffness (BASDAI question 6) 
and CRP (mg/l).23 24 ASDAS inactive disease (ASDAS ID) was 
deﬁ   ned as ASDAS <1.3, and major improvement in ASDAS 
(ASDAS MI) was deﬁ  ned as a decrease from baseline ≥2.0.25 
Treatment-emergent adverse events were those occurring on or 
after the ﬁ  rst dose of adalimumab, up to 70 days after the last 
adalimumab dose. Adverse events are reported as number of 
events and as rate of events per 100 patient-years.
Statistical analyses
All patients who received at least one dose of blinded or open-
label adalimumab were included. Observed analyses were 
used to determine the proportion of patients achieving clini-
cal responses after 1 and 5 years of adalimumab exposure and 
completers’ analyses were used to determine the stability of 
response among those patients who completed the 5-year study. 
Only patients in the original double-blind adalimumab treat-
ment group could have received 5 years of exposure.
Univariate regression analysis of long-term remission
Univariate logistic regression was used to evaluate factors 
hypothesised to be predictive of ASAS PR and ASDAS ID at 1 
and 5 years of adalimumab exposure. Continuous explanatory 
variables included age, disease duration and the following base-
line disease activity measures: BASFI, BASDAI, total back pain, 
patient and physician global assessments of disease activity and 
inﬂ  ammation (mean of BASDAI questions 5 and 6). Colinearity 
Table 1  Baseline demographics and disease characteristics
Variable Any ADA exposure (N=311)
Sex, n (%) male 233 (74.9)
Race, n (%) white 299 (96.1)
Age, mean (SD) years 42.3 (11.6)
HLA-B27+, n (%) 245 (78.8)
Disease duration, mean (SD) years 11.00 (9.5)
Abnormal CRP, n (%) ≥0.49 mg/dl 211 (67.8)
BASDAI, mean (SD) cm (0–10 VAS) 6.3 (1.7)
Patient global assessment, mean (SD) mm 
(0–100 VAS)*
63.6 (20.9)
Physician global assessment, mean (SD) mm 
(0–100 VAS)*
57.3 (18.6)
Total back pain, mean (SD) mm (0–100 VAS) 65.3 (21.1)
BASFI, mean (SD) mm (0–100 VAS) 53.8 (22.1)
Inﬂ  ammation, mean (SD) cm (0–10 VAS)† 6.7 (2.0)
≥1 syndesmophyte, n (%)‡ 188 (85.8)
*N=310.
†Mean of BASDAI question 5 and 6.
‡N=219.
ADA, adalimumab; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, 
Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; HLA, human 
leucocyte antigen; VAS, visual analogue scale.
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of tuberculosis or demyelinating disorder. Although there were 
no fatal adverse events, one non-treatment-emergent death 
occurred owing to adenocarcinoma at the gastro-oesophageal 
junction, with liver metastases >1.2 years after the patient dis-
continued adalimumab.
Predictors of long-term and sustained remission
Univariate analysis of long-term remission at 1 and 5 years 
of adalimumab treatment
Colinearity assessment of continuous explanatory baseline dis-
ease variables identiﬁ  ed signiﬁ  cant associations between all vari-
ables (p<0.001). The highest colinearity was identiﬁ  ed between 
total back pain, patient global assessment of disease activity, 
BASFI and BASDAI (correlation coefﬁ  cients, r=0.51–0.74), while 
physician global assessment of disease activity and morning 
stiffness had an intermediate level of colinearity (r=0.20–0.46).
Baseline characteristics including age, patient and physician 
global assessments of disease activity, total back pain, inﬂ  amma-
tion and BASFI generally showed signiﬁ  cant negative associa-
tions with long-term remission at 1 and 5 years of adalimumab 
exposure; however, these effects were relatively small (ﬁ  gure 2). 
The presence of syndesmophytes at initiation of adalimumab 
treatment was noted to be a signiﬁ  cant negative predictor of 
remission after 1 year of adalimumab treatment (OR (95% CI), 
p value; ASAS PR: 0.29 (0.13 to 0.65), p=0.003; ASDAS ID: 0.35 
(0.16– to 0.78), p=0.01), but not of remission after 5 years of 
treatment.
The strongest predictors of ASAS PR or ASDAS ID after 1 and 
5 years of adalimumab treatment were achievement of ASAS 
PR or ASDAS ID, respectively, at week 12 (ﬁ  gure 2). Patients 
who attained remission early were more than 10 times as likely 
to be in remission after 1 and 5 years of adalimumab treatment 
than those who did not achieve these disease states at week 
12 (p<0.001). Other measures of treatment response (ASAS20, 
ASAS40, ASDAS MI and BASDAI 50) after 12 weeks were also 
strongly predictive of long-term remission (OR ranged from 
approximately 3 to 9, p≤0.01).
Multivariate analysis of sustained remission
About half of the patients achieved a persistent state of disease 
remission. For ASAS PR, 141/311 (45%) patients demonstrated 
sustained remission at any time during the study, while 170/311 
(55%) patients met the criteria for sustained ASDAS ID. The 
median time to event, including the 6 months of sustained 
response, was 364 days for both outcomes (ﬁ  gure 3). The pro-
portion who achieved sustained remission and the median time 
to event were not appreciably different between the pool of 
patients with any adalimumab exposure (N=311) and the sub-
group with all explanatory variable data available for the multi-
variate regression (N=207, data not shown).
For both ASAS PR and ASDAS ID criteria, the respective 
achievement of these remission states at 12 weeks was the only 
signiﬁ   cant positive predictor of sustained disease remission 
  (ﬁ  gure 4). Reaching ASAS PR at week 12 resulted in a hazard ratio 
(95% CI, p value) for sustained ASAS PR of 2.49 (1.40 to 4.43, 
p=0.002). Patients who reached ASDAS ID after 12 weeks of 
adalimumab had a hazard ratio (95% CI, p value) of 3.18 (1.83 to 
5.53, p<0.001) for achieving sustained ASDAS ID. Additionally, 
decreased functional activity (higher BASFI) at baseline was sig-
niﬁ  cantly negatively associated with both sustained remission 
criteria, although the hazard ratios for both were close to 1.0 
(ASAS PR: 0.98 (0.96 to 0.99), p=0.002; ASDAS ID: 0.99 (0.97 
to 1.00), p=0.04). Indicators of baseline inﬂ  ammation (abnormal 
Adalimumab efﬁ  cacy through 5 years of treatment
Improvements in the signs and symptoms of AS observed 
after 1 year were sustained through 5 years of treatment with 
adalimumab among those patients originally randomised to 
adalimumab who completed the study (N=125) (ﬁ  gure  1). 
Based on an observed analysis among patients with 1 or 5 years 
exposure, approximately half of the patients who had 1 year 
of adalimumab exposure achieved ASAS40 (143/282, 50.7%), 
ASDAS MI (130/278, 46.8%) and BASDAI 50 (169/282, 59.9%) 
responses. At least one-third of patients experienced remission 
of disease activity after the ﬁ  rst year of treatment (ASAS PR: 
94/282, 33.3%; ASDAS ID: 118/282, 41.8%). The percentages 
of patients with good clinical responses were maintained among 
those originally randomised to adalimumab who completed 5 
years of the study (ASAS40: 88/125, 70.4%; ASDAS MI: 79/121, 
65.3%; BASDAI 50: 96/124, 77.4%). Among patients who had 
5 years of adalimumab exposure, the majority exhibited disease 
remission based on ASAS PR (63/124, 50.8%) or ASDAS ID 
(75/124, 60.5%) criteria.
Long-term safety
Over 1200 patient-years of adalimumab exposure were included 
in the long-term safety summary (table 2). There were no cases 
Figure 1  Percentages of patients achieving clinical response and 
remission states after 1 and 5 years of adalimumab treatment. 
Percentages based on patients originally randomised to adalimumab 
who completed the study and received 5 years of adalimumab 
(N=125). ASDAS MI: major improvement in ASDAS, decrease of ≥2.0; 
ASAS PR: ASAS partial remission; ASDAS ID: inactive disease, ASDAS 
<1.3. ASAS, Assessment in Spondyloarthritis International Society; 
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index.
Table 2  Numbers and rates of adverse events of interest with tumour 
necrosis factor inhibitor treatment in patients with any adalimumab 
exposure (N=311, 1201.1 patient-years)
  N (E/100 PYs)
Serious adverse events 140 (11.7)
Serious infections 17 (1.4)
Opportunistic infections* 12 (1.0)
Malignancies (excluding lymphoma and NMSC) 3 (0.2)
Lymphoma 1 (<0.1)
NMSC 5 (0.4)
Lupus-like syndrome 1 (<0.1)
Congestive heart failure-related 2 (0.2)
E, events; NMSC, non-melanoma skin cancer; PYs, patient-years.
*All mild to moderate candidiasis
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the type and rate of adverse events seen through 5 years of 
adalimumab treatment were consistent with previous study 
reports and the known safety proﬁ  le of adalimumab in other 
immune-mediated inﬂ  ammatory diseases.1 6 27 No new safety 
signals were noted.
Important therapeutic decisions are often made based on 
expected outcomes. Identifying factors that predict treatment 
response can assist clinicians in these management decisions. In 
a similar way, determining predictors of exceptional response, 
such as long-term disease remission over a long period, is help-
ful in shaping both the doctor’s and the patient’s expectations 
for chronic treatment. Previously published analyses predicting 
treatment response with anti-TNF treatment in patients with AS 
have examined short-term clinical responses (≤6 months) and 
mainly focused on improvement, not disease remission. This is 
the ﬁ  rst report in patients with AS of patterns and predictors of 
sustained remission, deﬁ  ned as ASAS PR or ASDAS ID for at 
least three consecutive study visits spanning a period of at least 
6 months.
CRP: 0.62 (0.40 to 1.00), p=0.048 and mean of BASDAI ques-
tions 5 and 6: 0.87 (0.77 to 0.97), p=0.015) were also signiﬁ  cantly 
negatively associated with sustained ASDAS ID, but not sus-
tained ASAS PR (ﬁ  gure 4).
DISCUSSION
The 5-year efﬁ  cacy and safety of adalimumab treatment in 
patients with AS from the ATLAS trial are consistent with the 
reported observations through 2 years of exposure.6 Nearly 
two-thirds of the original patient population completed the 
5-year study. Among those who received 5 years of adali-
mumab treatment, the majority of patients demonstrated 
clinical response or beneﬁ  t. Over half of the patients achieved 
remission based on criteria for ASAS PR (63/124, 50.8%) or 
ASDAS ID (75/124, 60.5%). Similar long-term data from the 
open-label extension of a randomised controlled trial of etaner-
cept in AS reported that 18/59 patients (30.5%) were in ASAS 
PR at 5 years.11 Inﬂ  iximab use through 3 years showed that 
15/46 patients (32.6%) demonstrated ASAS PR.26 The safety, 
Figure 2  Odds ratio for achieving long-term remission after 1 or 5 years of adalimumab treatment by univariate logistic regression. (A) ASAS partial 
remission at 1 year; (B) ASDAS inactive disease at 1 year; (C) ASAS partial remission at 5 years; (D) ASDAS inactive disease at 5 years. Bold type 
indicates p<0.05. ASDAS ID: inactive disease, ASDAS <1.3; ASDAS MI: major improvement in ASDAS, decrease of ≥2.0; ASAS PR: ASAS partial 
remission; BL: baseline; inﬂ  ammation: mean of BASDAI questions 5 and 6; PhGA: physician global assessment of disease activity; PtGA: patient 
global assessment of disease activity; TBP: total back pain; abnormal C-reactive protein (CRP): ≥0.49 mg/dl. ASAS, Assessment in Spondyloarthritis 
International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.
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response than baseline characteristics is supported by ﬁ  ndings 
from an open-label inﬂ   iximab study, which showed that an 
initial ASAS20 response at week 2 was predictive of ASAS20 
at week 10; unfortunately, the impact of clinical improvement 
after 2 weeks of treatment was not evaluated relative to longer-
term remission.13 Likewise, results presented here suggest that, 
more than the baseline disease characteristics, attainment of 
remission early in the course of treatment is predictive of long-
term treatment success.
About half of the patients achieved sustained remission, the 
majority of whom met these criteria within a year of treatment 
initiation. In multivariate analyses, attainment of either ASAS 
PR or ASDAS ID at 12 weeks eliminated most baseline patient 
and disease characteristics from predictive models. A similar 
relationship between early treatment response and sustained 
remission has been described in a cohort of patients with rheu-
matoid arthritis.29 Although these results might initially appear 
to suggest that baseline variables have no impact on attaining 
sustained remission, the inﬂ  uence of baseline characteristics on 
attaining remission at 12 weeks must be considered.
These results are in alignment with current recommenda-
tions for evaluating treatment response after at least 12 weeks 
of treatment.12 24 Achieving BASDAI 50 at week 12, in conjunc-
tion with expert opinion, has been identiﬁ  ed as an appropriate 
gauge for continuation of anti-TNF treatment; results presented 
here suggest that patients who are in remission after 12 weeks 
of treatment (either by ASAS PR or ASDAS ID) are more likely 
to achieve long-term and sustained remission with continued 
adalimumab treatment.
One of the strengths of this analysis is the length of follow-up. 
It is also the ﬁ  rst report to examine long-term remission by both 
ASAS PR and ASDAS ID criteria and the ﬁ  rst to demonstrate 
early attainment of remission as a predictor of long-term and 
sustained remission. Limitations of this study include the open-
label, uncontrolled nature of the long-term post hoc analysis. 
There may be other characteristics related to sustained disease 
control that were not considered. The use of observed and 
completers’ analyses may reﬂ  ect a positive selection bias, since 
patients who remain in the study are likely to be those who 
Analyses aimed at predicting clinical outcomes have identi-
ﬁ  ed shorter disease duration and the closely related variable of 
younger patient age as relevant factors for treatment response at 
3 or 6 months.15–17 19 20 A randomised controlled trial of adali-
mumab in non-radiographic axial spondyloarthritis also sug-
gested that younger age was associated with clinical outcomes 
after 1 year of treatment.28 Disease duration was not signiﬁ  cantly 
associated with long-term remission in the univariate models 
described here, a discrepancy possibly due to the limited num-
ber of patients with short disease durations. This study does 
support the hypothesis that better outcomes are achieved in 
younger patients, as age was a signiﬁ  cant negative predictor of 
long-term remission at 1 and 5 years of adalimumab treatment.
Baseline disease characteristics were often weakly predictive 
of long-term remission. Lower levels of baseline total back pain, 
inﬂ  ammation, patient and physician global assessments of dis-
ease activity, BASDAI and BASFI increased the probability of 
a patient achieving remission at 1 and 5 years of adalimumab 
treatment. Randomised controlled trials, cohort and registry 
data have shown associations of baseline BASFI with achieving 
a BASDAI 50 response after 3-6 months of treatment.14–19 These 
same studies identiﬁ   ed baseline CRP values as indicative of 
future response14–20; however, the focus was primarily on short-
term improvement and not long-term remission. An abnormal 
baseline CRP level was not a signiﬁ  cant predictor of long-term 
remission as shown in the analyses conducted with the 5-year 
data from ATLAS. This indicates that raised CRP should not be 
a mandatory requirement for treatment of AS with TNF inhibi-
tors. Patients with existing syndesmophytes at baseline were 
less likely to reach long-term remission in this study. Thus, 
initiation of anti-TNF treatment before the onset of new bone 
formation may enable a patient to achieve remission over the 
course of treatment.
In this study, the most notable factors that predicted long-
term remission at years 1 and 5 of adalimumab treatment were 
early treatment responses at week 12, particularly achievement 
of remission. Most previous reports did not consider initial 
response as a potential indicator of future success. The hypoth-
esis that short-term outcomes are more predictive of future 
Figure 3  Kaplan–Meier analysis for achieving sustained remission. N=311 patients who received at least 1 dose of adalimumab; patients who 
discontinued prematurely were not included at subsequent time points. Sustained remission was deﬁ  ned as ASAS partial remission (ASAS PR) or 
ASDAS inactive disease (ASDAS ID) for at least three consecutive study visits spanning at least 6 months. ASAS, Assessment in Spondyloarthritis 
International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score.
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use of adalimumab in patients with AS. Early achievement of 
remission with adalimumab was the most compelling predic-
tor of subsequent long-term and sustained remission in patients 
with AS.
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The 5-year ATLAS data conﬁ   rm that the early clinical 
improvements and safety proﬁ   le seen with adalimumab in 
patients with AS are maintained through 5 years of treatment, 
supporting a favourable beneﬁ  t:risk proﬁ  le for the long-term 
Figure 4  Odds ratio for achieving sustained remission by multivariate 
regression. (A) ASAS partial remission; (B) ASDAS inactive disease. 
Sustained remission was deﬁ  ned as ASAS partial remission or 
ASDAS inactive disease for at least three consecutive study visits 
spanning at least 6 months. Bold type indicates p<0.05. ASDAS 
ID: inactive disease, ASDAS <1.3; ASDAS MI: major improvement 
in ASDAS, decrease of ≥2.0; ASAS PR: ASAS partial remission; BL: 
baseline; inﬂ  ammation: mean of BASDAI questions 5 and 6; PhGA: 
physician global assessment of disease activity; PtGA: patient global 
assessment of disease activity; TBP: total back pain; abnormal 
C-reactive protein (CRP): ≥0.49 mg/dl; treatment group: randomisation 
to either adalimumab or placebo during the ﬁ  rst 24 weeks of the 
study. ASAS, Assessment in Spondyloarthritis International Society; 
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index.
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